Atheric Pharmaceutical, LLC was an American biopharmaceutical company based in Troy, Virginia.[1] It was founded in February 2016 by Robert Malone, Jill Glasspool-Malone and Jeffrey DiFrancesco.[2]
Atheric was focused on the “rapid development and commercialization of re-purposed drugs to prevent and treat Zika and other Flavivirus disease.”[3]
Personnel
| Name | Position | Notes |
|---|---|---|
| Robert Malone | Chief Executive Officer, Chief Scientific Officer, Co-Founder[4] | - |
| Jill Glasspool-Malone | Vice President of Pre-Clinical Research and External Relations | University of California, Davis, University of California, San Diego |
| Jeffrey DiFrancesco | Co-Founder[2:1] | - |
| Patricia Hommel | Business Development | Center for Innovative Technology (CIT), Chesapeake Innovation Center (CIC) |
| Diego Mezzogiorno | - | World Bank, United Nations Development Programme (UNDP) |
| James Talton | Advisor | Alchem Laboratories, Nanotherapeutics |
External links
Contact. Atheric Pharmaceutical. Retrieved June 6, 2017, from http://archive.today/2017.06.06-165445/http://www.atheric.com/contact-1 ↩︎
Atheric Pharmaceutical LLC. Gust. Retrieved February 25, 2023, from http://archive.today/2023.02.25-165658/https://gust.com/companies/atheric-pharmaceutical-llc ↩︎ ↩︎
Atheric Pharmaceutical - Crunchbase Company Profile & Funding. Crunchbase. Retrieved February 25, 2023, from https://www.crunchbase.com/organization/atheric-pharmaceutical ↩︎
The Team. Atheric Pharmaceutical. Retrieved July 14, 2017, from http://archive.today/2017.07.14-055404/http://www.atheric.com/team ↩︎
